{
    "clinical_study": {
        "@rank": "147814", 
        "arm_group": [
            {
                "arm_group_label": "Arm 1", 
                "arm_group_type": "Experimental", 
                "description": "Subjects will receive a single oral dose of 80 mg BAY85-3934 in the first period and placebo in the second period, separated by a wash-out period of at least 1 week."
            }, 
            {
                "arm_group_label": "Arm 2", 
                "arm_group_type": "Experimental", 
                "description": "Subjects will receive a single oral dose of 120 mg BAY85-3934 in the first period and placebo in the second period, separated by a wash-out period of at least 1 week."
            }, 
            {
                "arm_group_label": "Arm 3", 
                "arm_group_type": "Experimental", 
                "description": "Subjects will receive a single oral dose of 40 mg BAY85-3934 in the first period and placebo in the second period, separated by a wash-out period of at least 1 week. This is an optional dose escalation step."
            }, 
            {
                "arm_group_label": "Arm 4", 
                "arm_group_type": "Experimental", 
                "description": "Subjects will receive a single oral dose of 160 mg BAY85-3934 in the first period and placebo in the second period, separated by a wash-out period of at least 1 week. This is an optional dose escalation step."
            }
        ], 
        "brief_summary": {
            "textblock": "The phase I study will investigate the hemodynamic effects as well as safety, tolerability,\n      and pharmacokinetics of BAY 85-3934 in patients with chronic kidney disease (CKD).\n\n      For hemodynamic evaluation blood pressure, heart rate and cardiac output will be measured.\n      Blood samples will be taken for safety laboratory, the measurement of BAY 85-3934\n      concentrations and biomarkers.\n\n      A maximum of 4 dose-escalation steps are planned.  Each dose step consists of 2 study\n      periods which are separated by a wash-out period of at least 1 week.  Subjects will receive\n      in a cross-over design a single dose of either active drug or placebo in these periods\n      according to randomization. The planned dose steps are single oral doses of 80, 120mg and\n      optionally 40 and/ or 160 mg given as tablets."
        }, 
        "brief_title": "Dose Escalation Study to Investigate Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of BAY85-3934 in Subjects With Chronic Kidney Disease (CKD)", 
        "completion_date": {
            "#text": "July 2013", 
            "@type": "Actual"
        }, 
        "condition": "Kidney Diseases", 
        "condition_browse": {
            "mesh_term": [
                "Kidney Diseases", 
                "Renal Insufficiency, Chronic", 
                "Kidney Failure, Chronic"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Presence of chronic kidney disease (CKD) not on dialysis assessed by medical history\n             and eGFR (MDRD) = < 60 mL/min estimated at the pre-study visit\n\n          -  Stable renal disease, ie not expected to begin dialysis during the study\n\n          -  Systolic blood pressure =>110 mmHg and =<160 mmHg\n\n          -  Heart rate =<100 BPM\n\n          -  Hemoglobin = >9 g/dL\n\n          -  Female subjects without child-bearing potential, ie postmenopausal women with 12\n             months of spontaneous amenorrhea or with 6 months of spontaneous amenorrhea and serum\n             FSH levels >30 mIU/mL, women with 6 weeks post bilateral ovariectomy, women with\n             bilateral tubal ligation, and women with hysterectomy\n\n          -  Body mass index (BMI): = >18 and = < 35 kg/m2 at the pre-study visit\n\n        Exclusion Criteria:\n\n          -  Incompletely cured pre-existing diseases for which a relevant impairment of\n             absorption, distribution, metabolism, elimination or effects of the study drug is\n             assumed\n\n          -  Known hypersensitivity to the study drugs (active substances or excipients of the\n             preparations)\n\n          -  Known severe allergies, non-allergic drug reactions, or multiple drug allergies\n\n          -  Chronic heart failure, New York Heart Association (NYHA) III-IV\n\n          -  Coronary artery disease with uncured significant stenosis\n\n          -  Angina pectoris\n\n          -  Significant stenosis of cerebral vessels\n\n          -  Significant uncorrected rhythm or conduction disturbances such as a second- or\n             third-degree atrioventricular block without a cardiac pacemaker or episodes of\n             sustained ventricular tachycardia\n\n          -  Subjects with impaired liver function (Child Pugh B to C based on medical history)\n\n          -  History of thrombotic or thromboembolic events (eg myocardial infarction, stroke,\n             transient ischemic attack, deep vein thrombosis, pulmonary embolism) within the\n             recent 6 months\n\n          -  Proliferative choroidal or retinal disease, such as neovascular age-related macular\n             degeneration or proliferative diabetic retinopathy that required or is likely to\n             require treatment (intraocular injections or laser photocoagulation) during the study\n\n          -  Subjects with a history of malignant disease during the last 5 years\n\n          -  Treatment with EPO-stimulating agents (ESA) or rhEPO within the last 2 weeks before\n             first intake of study drug\n\n          -  Suspicion of drug or alcohol abuse\n\n          -  Positive results for hepatitis B virus surface antigen (HBsAg), hepatitis C virus\n             antibodies (anti-HCV), human immune deficiency virus antibodies (anti-HIV 1+2) at the\n             pre-study visit"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "79 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "48", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "September 3, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01679587", 
            "org_study_id": "16370", 
            "secondary_id": "2012-002375-33"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Arm 1", 
                    "Arm 2", 
                    "Arm 3", 
                    "Arm 4"
                ], 
                "description": "Four escalated single oral dose steps of BAY85-3934 will be given - step 1 - 40mg (optional), step 2 - 80mg; step 3 - 120mg step 4 - 160mg (optional). Per arm one dose step will be conducted.", 
                "intervention_name": "BAY85-3934", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Arm 1", 
                    "Arm 2", 
                    "Arm 3", 
                    "Arm 4"
                ], 
                "description": "Single oral dose of matching placebo will be given in each treatment step", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "No", 
        "lastchanged_date": "March 6, 2014", 
        "link": [
            {
                "description": "Click here and search for drug information provided by the FDA.", 
                "url": "http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm"
            }, 
            {
                "description": "Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.", 
                "url": "http://www.fda.gov/medwatch/safety.htm"
            }
        ], 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "M\u00fcnchen", 
                        "country": "Germany", 
                        "state": "Bayern", 
                        "zip": "81241"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "M\u00f6nchengladbach", 
                        "country": "Germany", 
                        "state": "Nordrhein-Westfalen", 
                        "zip": "41061"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kiel", 
                        "country": "Germany", 
                        "state": "Schleswig-Holstein", 
                        "zip": "24105"
                    }
                }
            }
        ], 
        "location_countries": {
            "country": "Germany"
        }, 
        "number_of_arms": "4", 
        "official_title": "Multicenter, Randomized, Single-blind, Placebo-controlled, Combined 2-fold Cross-over and Group-comparison, Dose Escalation Study to Investigate Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of Single Oral Doses of BAY85 3934 in Subjects With Chronic Kidney Disease (CKD)", 
        "overall_official": {
            "affiliation": "Bayer", 
            "last_name": "Bayer Study Director", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Germany: Federal Institute for Drugs and Medical Devices", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "February 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "Number of participants with adverse events as a measure of safety and tolerability of BAY85-3934", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 30 days after last dosing"
            }, 
            {
                "measure": "Blood pressure (systolic, diastolic, mean)", 
                "safety_issue": "Yes", 
                "time_frame": "Day 1"
            }, 
            {
                "description": "non-invasive stroke volume and cardiac output", 
                "measure": "Hemodynamic assessment", 
                "safety_issue": "Yes", 
                "time_frame": "Day 1"
            }, 
            {
                "measure": "Heart rate and heart rate over 1 min", 
                "safety_issue": "Yes", 
                "time_frame": "Day 1"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01679587"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Pharmacokinetic profile determined by plasma concentration of BAY85-3934", 
                "safety_issue": "No", 
                "time_frame": "15 min, 30 min, 45 min, 1 h, 1.5 h, 2 h, 3 h, 4 h, 6 h, 8 h, 10 h, 12 h, 24 h,36 h, 48 h post dose"
            }, 
            {
                "description": "Hematology profile includes blood concentration of erythropoietin, reticulocytes, erythrocytes, hemoglobin, hematocrit, and exploratory biomarkers.", 
                "measure": "Change of hematology profile", 
                "safety_issue": "No", 
                "time_frame": "From baseline to Day 1 after single dose"
            }, 
            {
                "measure": "Number of subjects with abnormal Electrocardiogram (ECG) measured by QTcBazett > 500 msec", 
                "safety_issue": "No", 
                "time_frame": "Day 1"
            }, 
            {
                "measure": "Number of subjects with clinically relevant laboratory deviations.", 
                "safety_issue": "Yes", 
                "time_frame": "Up to Day 3"
            }
        ], 
        "source": "Bayer", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Bayer", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "September 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject)", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}